Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,187 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05491889 | Outcome of Hepatocellular Carcinoma Patients With Portal Vein Thrombosis After Trans-Arterial Chemo Embolization | unknown | — | 30 | Assiut UniversityOTHER | 0 | Aug 8, 2022 | clinicaltrials |
| NCT05290116 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Yunfei YuanOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05490147 |
| Effect of Low Tidal Ventilation on Intraoperative Bleeding in Laparoscopic Major Hepatectomy |
| unknown |
| N/A |
| 58 |
| Seoul National University HospitalOTHER |
| 1 |
| Aug 5, 2022 |
| clinicaltrials |
| NCT05487443 | The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies | unknown | Phase 2 / Phase 3 | 50 | First People's Hospital of HangzhouOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT03838796 | Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma | unknown | N/A | 297 | Fudan UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05472896 | TACE With Dicycloplatin(TP21) in Unresectable HCC | unknown | Phase 3 | 332 | Gao-jun TengOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05458791 | Intra-arterial Perfusion in Interventional Radiology | unknown | — | 20 | Palo Alto Veterans Institute for ResearchOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04362449 | Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration | unknown | Phase 2 | 30 | Imperial College Healthcare NHS TrustOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05449860 | Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma With Twin Cooled-wet Electrodes | unknown | N/A | 102 | Seoul National University HospitalOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT04637048 | Observational Study on Patients With Hepatobiliary Tumors | unknown | — | 1,000 | Gang Chen, MDOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT04401709 | Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer | unknown | Phase 3 | 490 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05339919 | Relationship Between Liver Cancer and Sarcopenia | unknown | — | 1,200 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05397860 | Radiofrequency Ablation With Gradual Radiofrequency Energy Increment for Hepatocellular Carcinoma Treatment | unknown | N/A | 120 | Seoul National University HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05418543 | CH-EUS in Diagnosis of Inoperable Bile Duct Tumors | unknown | N/A | 40 | Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian FodorOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05420922 | Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC | unknown | — | 2,000 | Tongji HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05417230 | RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 | unknown | Phase 2 | 29 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Jun 14, 2022 | clinicaltrials |
| NCT04174781 | Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC | unknown | Phase 2 | 61 | Zhejiang UniversityOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT05411926 | Effect of PD-1 /PD-L1 Inhibitor Therapy Before Liver Transplantation on Acute Rejection After Liver Transplantation in Patients With Hepatocellular Carcinoma | unknown | — | 30 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT05002452 | Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCC | unknown | — | 150 | Sun Yat-sen UniversityOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT03898895 | COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer(CORRECT) | unknown | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05396937 | Efficacy and Safety of T+A+RAD in HCC | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT05391867 | Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma | unknown | N/A | 70 | Sir Salimullah Medical College Mitford HospitalOTHER_GOV | 1 | May 26, 2022 | clinicaltrials |
| NCT05231382 | Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma | unknown | Phase 3 | 426 | Sun Yat-sen UniversityOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05220020 | TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer | unknown | Phase 3 | 299 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05383066 | Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer | unknown | — | 490 | Peking University First HospitalOTHER | 0 | May 19, 2022 | clinicaltrials |
| NCT04843176 | Artificial Intelligence vs. LIRADS in Diagnosing HCC on CT | unknown | N/A | 250 | The University of Hong KongOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT05376943 | Possible Differences in HCC Course Depending on DAA Treatment | unknown | — | 100 | Medical University of WarsawOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05343832 | Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients | unknown | — | 4,816 | Genetron HealthINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT05369650 | To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients | unknown | N/A | 120 | West China HospitalOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT05369988 | VALIDATION OF THE VIBe INTRAOPERATIVE BLEEDING SCALE IN LIVER SURGERY | unknown | — | 259 | Hospital Miguel ServetOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT05339321 | Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC | unknown | Phase 1 | 36 | Peking Union Medical College HospitalOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05363722 | A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 80 | Shanghai Zhongshan HospitalOTHER | 0 | May 6, 2022 | clinicaltrials |
| NCT05214339 | A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05111366 | TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection(ALTER-H006) | unknown | Phase 2 | 37 | Xianhai MaoOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT04564313 | Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation | unknown | Phase 1 | 20 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT05290220 | HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Shanghai Henlius BiotechINDUSTRY | 0 | May 3, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05357196 | PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 68 | SciClone PharmaceuticalsINDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT04487704 | Camrelizumab Utilization on Patients With Advanced Liver Cancer | unknown | N/A | 1,000 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05353894 | Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers | unknown | Phase 1 | 27 | Genoscience PharmaINDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT02794337 | TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer(TACE-SBRT) | unknown | Phase 2 / Phase 3 | 67 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05339581 | IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation(iPLENTY-pvtt) | unknown | N/A | 78 | RenJi HospitalOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05171439 | Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples | unknown | Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05327582 | An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | unknown | Phase 1 / Phase 2 | 65 | Chinese PLA General HospitalOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05327907 | Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma | unknown | — | 300 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03958019 | Rehabilitation Strategies Following Oesophagogastric and Hepatopancreaticobiliary Cancer(RESTORE II) | unknown | N/A | 120 | University of Dublin, Trinity CollegeOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT03223818 | The Impact of Fast-track Perioperative Program After Liver Resection in Hong Kong Chinese Patients | unknown | N/A | 94 | Chinese University of Hong KongOTHER | 1 | Apr 12, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Aug 8, 2022source: clinicaltrials